Table 2.
Characteristics | Number of patients |
---|---|
Age (years), median (range) | 57 (24–83) |
Sex | |
Female | 36 (92.3%) |
Male | 3 (7.7%) |
Types of scleroderma | |
Diffuse | 11 (28.2%) |
Limited | 23 (59.0%) |
NA | 5 (12.8%) |
Duration from onset of SSc to onset of PCI (years), median (range) | 6 (0–30) |
Past corticosteroid therapy | |
Present | 24 (61.5%) |
Autoantibody positivity | |
Antinuclear antibody | 33 (84.6%) |
Anticentromere antibody | 7 (18.0%) |
Anti-Scl-70 antibody | 3 (7.7%) |
Negative | 6 (15.4%) |
Overlap syndrome | |
Polymyositis/scleroderma | 8 (20.5%) |
Sjogren's syndrome/scleroderma | 1 (2.6%) |
Site of PCI | |
Small intestine | 27 (69.2%) |
Small and large intestine | 2 (5.1%) |
Large intestine | 2 (5.1%) |
NA | 8 (20.5%) |
Symptoms and signs | |
Abdominal distention | 32 (82.1%) |
Abdominal pain | 13 (33.3%) |
Abdominal tenderness | 11 (28.2%) |
Nausea/vomiting | 9 (23.1%) |
Weight loss | 8 (20.5%) |
Anorexia | 8 (20.5%) |
Constipation | 5 (12.8%) |
Fatigue | 5 (12.8%) |
Diarrhea | 5 (12.8%) |
Peritoneal irritation sign | 2 (5.1%) |
Diagnostic modalities | |
Upper gastrointestinal series | 2 (5.1%) |
Plain X-ray film | 10 (25.6%) |
CT | 11 (28.2%) |
Plain X-ray film and CT | 11 (28.2%) |
Exploratory laparotomy | 5 (12.8%) |
Pneumoperitoneum | |
Present | 34 (87.2%) |
Absent | 5 (12.8%) |
Treatment | |
Antibiotics | 13 (33.3%) |
Oxygen therapy | 9 (23.1%) |
Octreotide | 2 (5.1%) |
Surgery | 2 (5.1%) |
Treatments other than the above-mentioned ones (symptomatic therapy combined with fluid therapy or elemental diet, etc.) | 15 (38.5%) |
SSc: systemic sclerosis; PCI: pneumatosis cystoides intestinalis; NA: not available; CT: computed tomography.